Neuromuscular Blocking Agents

ApprovedSmall molecule

UUniversity of Maryland, Baltimore

Neuromuscular Blocking Agents is one of 46 small molecule programs targeting Hypothermia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypothermiaActive, not recruiting

Acute Respiratory Distress SyndromeActive, not recruiting

HypothermiaPhase 2

Active, not recruiting

Acute Respiratory Distress SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

146 competitors in Acute Respiratory Distress Syndrome

#DrugCompanyPhaseTrials

Medrol

Pfizer

Phase 3

3 2

Plaquenil

Alnylam Pharmaceuticals

Phase 3

1 3

Zulresso

Biogen

Phase 3

1 4

Activase

Ultomiris

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

3 7

Inomax

MMallinckrodt

Phase 3

2 8

Vafseo

AAkebia Therapeutics

Phase 3

2 9

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 10

Nizoral

WWim Janssens

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Hypothermia

NCT04545424

Clinical

Trials by Indication[1]

Neuromuscular Blockade2 trials

Paediatric Ards Neuromuscular Blockade Study

Terminated·UUniversity Medical Center Groningen·Phase 4·NCT02902055·3 enrolled

Neuromuscular Blockade in the Intentive Care Unit, an Observational Study.

Completed·FFrench Society for Intensive Care··NCT04028362·282 enrolled

Hypothermia2 trials

Trial of Therapeutic Hypothermia in Patients With ARDS

Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT04545424·340 enrolled

Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS

Withdrawn·UUniversity of Maryland, Baltimore·Phase 2·NCT03376854

Neostigmine1 trial

Comparison of Sugammadex and Neostigmine During PACU Stay

Not yet recruiting·UUniversity of South Florida·Phase 3·NCT04096144·50 enrolled

Complication1 trial

Avoiding Neuromuscular Blockers to Reduce Complications

Terminated·—·Phase 4·NCT03962725·3 enrolled

Acute Respiratory Distress Syndrome1 trial

Individualized Positive End-expiratory Pressure Guided by End-expiratory Lung Volume in the Acute Respiratory Distress Syndrome

Terminated·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 3·NCT04012073·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Neuromuscular Blocking Agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neuromuscular Blocking Agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neuromuscular Blocking Agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Maryland, Baltimore

Neuromuscular Blocking Agents

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Neuromuscular Blockade2 trials

Hypothermia2 trials

Neostigmine1 trial

Complication1 trial

Acute Respiratory Distress Syndrome1 trial

References

Drug Info

Quick Facts

Related News